Literature DB >> 15642764

Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model.

Guilherme V Silva1, Silvio Litovsky, Joao A R Assad, Andre L S Sousa, Bradley J Martin, Deborah Vela, Stephanie C Coulter, Jing Lin, Judy Ober, William K Vaughn, Rodrigo V C Branco, Edie M Oliveira, Rumin He, Yong-Jian Geng, James T Willerson, Emerson C Perin.   

Abstract

BACKGROUND: Bone marrow-derived stem cells are under investigation as a treatment for ischemic heart disease. Mesenchymal stem cells (MSCs) have been used preferentially in the acute ischemia model; data in the chronic ischemia model are lacking. METHODS AND
RESULTS: Twelve dogs underwent ameroid constrictor placement. Thirty days later, they received intramyocardial injections of either MSCs (100x10(6) MSCs/10 mL saline) (n=6) or saline only (10 mL) (controls) (n=6). All were euthanized at 60 days. Resting and stress 2D echocardiography was performed at 30 and 60 days after ameroid placement. White blood cell count (WBC), C-reactive protein (CRP), creatine kinase MB (CK-MB), and troponin I levels were measured. Histopathological and immunohistochemical analyses were performed. Mean left ventricular ejection fraction was similar in both groups at baseline but significantly higher in treated dogs at 60 days. WBC and CRP levels were similar over time in both groups. CK-MB and troponin I increased from baseline to 48 hours, eventually returning to baseline. There was a trend toward reduced fibrosis and greater vascular density in the treated group. MSCs colocalized with endothelial and smooth muscle cells but not with myocytes.
CONCLUSIONS: In a canine chronic ischemia model, MSCs differentiated into smooth muscle cells and endothelial cells, resulting in increased vascularity and improved cardiac function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642764     DOI: 10.1161/01.CIR.0000151812.86142.45

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  244 in total

1.  Intravenous administration of allogeneic Wharton jelly-derived mesenchymal stem cells for treatment of dogs with congestive heart failure secondary to myxomatous mitral valve disease.

Authors:  Vicky K Yang; Dawn M Meola; Airiel Davis; Bruce Barton; Andrew M Hoffman
Journal:  Am J Vet Res       Date:  2021-06       Impact factor: 1.156

Review 2.  Molecular mediators of mesenchymal stem cell biology.

Authors:  Maria P Alfaro; Sarika Saraswati; Pampee P Young
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

3.  Cardiac function in dogs with chronic Chagas cardiomyopathy undergoing autologous stem cell transplantation into the coronary arteries.

Authors:  Marlos G Sousa; Daniel Paulino-Junior; João P E Pascon; Gláucia B Pereira-Neto; Roberta Carareto; Tatiana Champion; Aparecido A Camacho
Journal:  Can Vet J       Date:  2011-08       Impact factor: 1.008

Review 4.  Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step.

Authors:  James D Richardson; Adam J Nelson; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley; Peter J Psaltis
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 5.  Stem cell therapy for ischemic heart disease.

Authors:  Mohammad Nurulqadr Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

6.  Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium.

Authors:  Jing Huang; Zhiping Zhang; Jian Guo; Aiguo Ni; Arjun Deb; Lunan Zhang; Maria Mirotsou; Richard E Pratt; Victor J Dzau
Journal:  Circ Res       Date:  2010-04-08       Impact factor: 17.367

Review 7.  Endoventricular electromechanical mapping-the diagnostic and therapeutic utility of the NOGA XP Cardiac Navigation System.

Authors:  Peter J Psaltis; Stephen G Worthley
Journal:  J Cardiovasc Transl Res       Date:  2008-12-10       Impact factor: 4.132

8.  Stem cell update: highlights from the 2010 Lugano Stem Cell Meeting.

Authors:  Silvana Bardelli; Giuseppe Astori; Daniel Sürder; Tiziano Tallone; Andre Terzic; Gianni Soldati; Tiziano Moccetti
Journal:  J Cardiovasc Transl Res       Date:  2010-10-30       Impact factor: 4.132

Review 9.  Mesenchymal stem cell-based gene therapy for erectile dysfunction.

Authors:  J H Kim; H J Lee; Y S Song
Journal:  Int J Impot Res       Date:  2016-02-18       Impact factor: 2.896

10.  Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells.

Authors:  Izuagie Attairu Ikhapoh; Christopher J Pelham; Devendra K Agrawal
Journal:  Differentiation       Date:  2015-04-23       Impact factor: 3.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.